Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2551-2555

  Jensen, Rasmus Hare ^a   Astvad, Karen Marie Thyssen ^a   Silva, Luis Vale ^b   Sanglard, Dominique ^b   Jørgensen, Rene ^a   Nielsen, Kristian Fog ^c   Mathiasen, Estella Glintborg ^a,c   Doroudian, Ghazalel ^d   Perlin, David Scott ^e   Arendrup, Maiken Cavling ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Antifungal resistance; Molecular typing; Mycology; Resistance mechanisms

Indexed keywords

AMINO ACID; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; ERGOSTEROL; FLUCONAZOLE; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; FUNGAL DNA;

ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIFUNGAL RESISTANCE; ARTICLE; BACTERIAL GENE; CANDIDA ALBICANS; CASE REPORT; CDR1 GENE; CDR2 GENE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLON BIOPSY; DNA SEQUENCE; ERG11 GENE; ERG2 GENE; ESOPHAGUS CANDIDIASIS; FECES ANALYSIS; FKS1 GENE; FRAMESHIFT MUTATION; GALLERIA MELLONELLA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MANTEL HAENSZEL TEST; MASS FRAGMENTOGRAPHY; MEDICAL HISTORY; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; OROPHARYNX CANDIDIASIS; PANCYTOPENIA; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; STEM CELL TRANSPLANTATION; TAC1 GENE; ULTRAVIOLET SPECTROPHOTOMETRY; VIRULENCE; AGED; ANIMAL; CANDIDIASIS; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; GENETICS; GENOTYPE; LEPIDOPTERA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; MUTATION; SURVIVAL ANALYSIS;

AGED; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; DNA, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; GENOTYPE; HUMANS; LEPIDOPTERA; MALE; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; MUTATION; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; VIRULENCE;

EID: 84954271426     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv140     Document Type: Article

References (30)

1. Cuenca-Estrella M. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. Clin Microbiol Infect 2014; 20: 54-9.
2. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
3. Silver PM, Oliver BG, White TC. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell 2004; 3: 1391-7.
4. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006; 313: 367-70.
5. Albertson GD, Niimi M, Cannon RD et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835-41.
6. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 2014; 27: 484-92.
7. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E246-7.
8. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C et al. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 2014; 57: 377-9.
9. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C et al. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013; 16: 81-95.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Fourth Informational Supplement M27-S4. Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2012.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-S4. CLSI, Wayne, PA, USA, 2008.
12. Bougnoux M-E, Morand S, Enfert C et al. Usefulness of multilocus sequence typing for characterization of clinical isolates of Candida albicans. J Clin Microbiol 2002; 40: 1290-7.
13. Pierson CA, Eckstein J, Barbuch R et al. Ergosterol gene expression in wild-type and ergosterol-deficient mutants of Candida albicans. Med Mycol 2004; 42: 385-9.
14. Lee M-K, Williams LE, Warnock DW et al. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-24.
15. Lohberger A, Coste AT, Sanglard D. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryot Cell 2014; 13: 127-42.
16. Sanglard D, Ischer F, Parkinson T et al. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404-12.
17. Nielsen KF, Madsen JO. Determination of ergosterol on mouldy building materials using isotope dilution and gas chromatography-tandem mass spectrometry. J Chromatogr A 2000; 898: 227-34.
18. Scorzoni L, de Lucas MP, Mesa-Arango AC et al. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile. PLoS One 2013; 8: e60047.
19. Flowers SA, Colón B, Whaley SG et al. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 2015; 59: 450-60.
20. Chau AS, Mendrick CA, Sabatelli FJ et al. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48: 2124-31.
21. Song JL, Harry JB, Eastman RT et al. The Candida albicans lanosterol 14-α-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother 2004; 48: 1136-44.
22. Oliver BG, Song JL, Choiniere JH et al. Cis-acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryot Cell 2007; 6: 2231-9.
23. Morio F, Pagniez F, Besse M et al. Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. Int J Antimicrob Agents 2013; 42: 410-5.
24. Coste AT, Karababa M, Ischer F et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639-52.
25. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
26. Hull CM, Bader O, Parker JE et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother 2012; 56: 6417-21.
27. 197 of the human emopamil binding protein are required for in vivo sterol Δ8-Δ7 isomerization. Biochemistry 1999; 38: 1119-27.
28. Young LY, Hull CM, Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother 2003; 47: 2717-24.
29. Ben-Ami R, Garcia-Effron G, Lewis RE et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 2011; 204: 626-35.
30. Kumar R, Shukla PK. Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans. Fungal Biol 2010; 114: 189-97.